Dr. Albert Bourla became the CEO of Pfiz­er in Jan­u­ary 2019. He began his career at the com­pa­ny in 1993, in the Ani­mal Health Divi­sion as tech­ni­cal direc­tor of Greece, and has served in numer­ous exec­u­tive posi­tions with­in the com­pa­ny, includ­ing COO, Group Pres­i­dent of Pfiz­er Inno­v­a­tive Health, and Group Pres­i­dent of Pfiz­er’s Glob­al Vac­cines, Oncol­o­gy, and Con­sumer Health­care busi­ness. He is a doc­tor of vet­eri­nary med­i­cine and holds a PhD in the Biotech­nol­o­gy of Repro­duc­tion from the Vet­eri­nary School of Aris­to­tle Uni­ver­si­ty. In addi­tion to his respon­si­bil­i­ties at Pfiz­er, Dr. Bourla is on the exec­u­tive com­mit­tee of The Part­ner­ship for New York City; a direc­tor on mul­ti­ple boards, includ­ing Pfiz­er Inc., PhRMA, and Cat­a­lyst; a Trustee of the Unit­ed States Coun­cil for Inter­na­tion­al Busi­ness; and a mem­ber of the Busi­ness Round­table and the Busi­ness Coun­cil. In 2020, Dr. Bourla was named Amer­i­ca’s top CEO in the phar­ma­ceu­ti­cals sec­tor by Insti­tu­tion­al Investor magazine.